A study on drug utilization evaluation in patients admitted with cardiovascular diseases at a tertiary care hospital was written by Hussain, Yousuf Md;Sultana, Syeda Juveria;Batool, Syeda;Prakash, J. Sai;Dussa, Kanchana N.;Unnisa, Mehraj. And the article was included in International Journal of Pharmacy and Pharmaceutical Research in 2021.Application of 83799-24-0 The following contents are mentioned in the article:
Cardiovascular diseases have become a major cause of morbidity and mortality globally. A prospective observational study was carried out in an inpatient department of cardiol. in a tertiary care hospital. The duration of the study was 4 mo i.e., from Oct. 2018 to Jan. 2019. The data was obtained from the patient′s medical record and was documented in the especially designed data collection form. One hundred and forty four patients were enrolled in the study. In our study 70.1% were male and 29.9% were female. Maximum number of patients i.e., 35.4% was in the age group of 51-60 years. In the present study, the prevalence of coronary artery disease was high. Hypertension and Diabetes were the most common co-morbid conditions observed The study showed higher incidence of drug use as single agents (83.36%) which is appreciable. Most commonly prescribed categories of cardiovascular drugs were antihypertensives (24.06%) and antiplatelets (23.31%) indicating high prevalence of hypertension and coronary artery disease in patients. Along with brand name, Generic name of the drug was mentioned in every prescription. Antibiotics were prescribed in 32.64% patients and injection was prescribed in 76.39% patients. Extensive polypharmacy (10.2 drugs per prescription) was noticed in the prescriptions. The prescribing pattern of drugs can be improved by reducing the number of drugs per prescription. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application of 83799-24-0).
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. The piperidine moiety constitutes an important building block for the synthesis of a variety of bioactive natural products, alkaloids and other drugs. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Application of 83799-24-0
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem